- €48.78bn
- €44.92bn
- $4.15bn
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles
Brief: Argenx Brings Neuromuscular Leadership To AAN 2026 With New Data Supporting Broader Vyvgart Use Across MG And CIDP
Netherlands' Argenx Q4 sales rise 90%, posts first profitable year
Brief: Argenx Reports $1.3 Billion In Q4 Global Product Net Sales
Brief: Argenx Q4 Net Income USD 532.95 Million
Brief: Argenx: Positive Topline Results From Phase 3 Adapt Oculus Trial Of Vyvgart In oMG
Argenx shares climb as FDA reviews Vyvgart additional application
Brief: Argenx: FDA Accepts Priority Review sBLA for Vyvgart in Seronegative gMG
Brief: Argenx Preliminary FY Global Product Net Sales $4.15 Bln
Europe-US relisting trend: $1 trln more in store
Brief: Karen Massey To Become CEO Of Argenx
Argenx seen down after halt to eye disease studies for efgartigimod
Brief: Argenx: UplighTED Studies Of Efgartigimod SC In Thyroid Eye Disease To Be Discontinued
Europe Research Roundup: Auto1 Group, Roche Holding, Sanofi
Brief: ArgenX Announces Results Of Extraordinary General Meeting Of Shareholders
U.S. RESEARCH ROUNDUP-Affiliated Managers Group, Argenx SE, Cardinal Health Inc